background: Prevalence of overweight and obesity is rising. Hence, it is likely that a higher proportion of women undergoing assisted reproduction treatment are overweight or obese.
Introduction
According to the World Health Organisation (WHO) classification (Table I ) approximately 30% of women between 25 and 44 years of age are overweight and 20% are obese (http://www.wvdhhr.org/ bph/oehp/obesity/define.htm). Along with conditions such as diabetes, hypertension, cardiovascular diseases and musculoskeletal diseases, obese women are more likely to experience reproductive problems (Clark et al., 1998) . In particular, overweight women are known to be at a higher risk of menstrual dysfunction and anovulation, possibly due to altered secretion of pulsatile GnRH, resulting in altered SHBG (sex hormone binding globulin), ovarian and adrenal androgens and lutenizing hormone (Clark et al., 1995) .
Recent Guidance issued by the British Fertility Society (BFS) recommends that infertility treatment should be deferred until the body mass index (BMI) of the female partner is below 35 kg/m 2 .
For younger women, with good ovarian reserve, for whom time is less of an issue, a reduction in BMI to below 30 kg/m 2 has been advocated (Balen and Anderson, 2007) . The rising prevalence of overweight and obese women in the general population is likely to result in increasing numbers of women with high BMI presenting for assisted reproduction treatment (ART). Overweight and obese women have increased requirements for gonadotrophins during IVF treatment (Fedorcsak et al., 2004) , a higher risk of miscarriage (Wang et al., 2000) and higher complication rates in pregnancy (Ramsay et al., 2006; Yu et al., 2006) . While it is anticipated that treatment will be more expensive in this group, no study has actually explored the actual health care cost of ART in overweight and obese women.
At the present time, criteria for access to IVF in some health care settings include strict upper limits for BMI (Farquhar, 2006; Gillet et al., 2006; Zachariah et al., 2006) . The aim of this study was to estimate and compare the cost per live birth across different BMI groups (as defined by WHO). We estimated total health care costs (incorporating IVF treatment costs, early pregnancy and antenatal care costs, using routine patient level resource use data) for women undergoing their first IVF treatment at our centre between 1997 and 2006.
Materials and Methods
In the UK, the Human Fertilization and Embryology Authority (HFEA) regulations prohibit identification of women undergoing IVF and linkage of their data to other databases by any individual(s) not directly connected with the provision of IVF. The IVF Unit in Aberdeen is the only one in the North East of Scotland region, providing tertiary level fertility services for the following regions: Grampian, Highland, Shetland and Orkney. All women in Aberdeen City District deliver at the Aberdeen Maternity Hospital, which is the only hospital in the state or private sector offering maternity services in Aberdeen. It is thus possible for clinicians based in the IVF Unit (who are also obstetricians in the Maternity Hospital) and the Data Manager involved with both datasets (who is named on the HFEA licence and is allowed access to IVF data) to link the IVF database (which records details of all IVF cycles) with the obstetric database (Aberdeen Maternity Neonatal Database). The Aberdeen Reproduction Unit Database (ARUD) logs all IVF events while the Aberdeen Maternity and Neonatal Databank (AMND) records and stores information on all pregnancy events occurring in Aberdeen city and district from the 1950s. The co-existence of the two population-based datasets allows an unique opportunity to do cross-sectional studies, such as this.
Validity checks
Data in the AMND are entered concurrently by dedicated staff. Regular validity checks are in place for both the databases.
Aberdeen Reproduction Unit Database
The statistics from ARUD are validated against annual reports from the HFEA related to all cycles undertaken and outcomes. They are also used for monthly analysis of key performance indicators, which are checked against laboratory records.
Aberdeen Maternity and Neonatal Databank
Completeness of the database is checked against the number of deliveries recorded in the National Health Service records office at the end of each year. Surveys and case note reviews have found the data to be over 90% accurate with regards to the variables studied.
Ethical approval
The study was approved by the North of Scotland Research Ethics Service (07/S0802/9).
Data collection
The history and treatment details of the participants are recorded in the ARUD. Following approval from the appropriate Caldicott Guardians, clinical details of women who had undergone their first cycle of assisted conception between 1997 and 2006 were extracted from ARUD. They were divided into five BMI groups based on WHO criteria (,18.5, 18.5 -24.9, 25 -29.9, 30 -34.5 and 35) . BMI was recorded within 3 months of commencing a fresh IVF cycle. All women who did not have their BMI recorded (after cross-checking from case notes) were excluded from this study. Women undergoing cycles with donated oocytes were also excluded. Data were extracted from ARUD on the following: BMI, age of the female partner, year of treatment, duration of infertility, primary cause of infertility, total dose of gonadotrophins used for ovarian stimulation, number of ultrasound scans for monitoring, number of blood tests for monitoring, whether or not oocyte recovery and embryo transfer were done, evidence and degree of ovarian hyperstimulation (OHSS) and outcome of pregnancy (no pregnancy, biochemical pregnancy, miscarriage/ectopic or ongoing pregnancy). Ongoing pregnancy was defined as any pregnancy with positive fetal heart visualized on ultrasound at 11 weeks of gestation. All women who went on to deliver in Aberdeen were identified and their details linked with the AMND in order to obtain obstetric and perinatal details. Obstetric details on women from other areas of Grampian and Highland who had successful IVF treatment in Aberdeen but did not deliver locally could not be traced as current HFEA regulations did not allow data linkage out with Aberdeen. However the outcome of their pregnancies was available from the ARUD, as were data on resource use up to 11 weeks of pregnancy.
After obtaining approval from the appropriate Caldicott Guardians the following data were extracted from the AMND for all ongoing pregnancies: complications of pregnancy (pre-eclamptic toxaemia, diabetes and ante-partum haemorrhage), mode of delivery and neonatal admissions. In addition, the number of antenatal visits, ultrasound scans and inpatient days were manually extracted for each patient for the pregnancy following the first IVF cycle using patient explorer (PAS) in the web-based system.
Any outliers or missing data were cross-checked from the case notes. If a patient had more than one entry into AMND, only the pregnancy event following the IVF treatment cycle was included. Delivery matches that were not associated with a treatment cycle were excluded.
Protocols
A standard long protocol for ovarian stimulation was used for IVF. The initial stimulatory dose of follicle-stimulating hormone (FSH) was determined by the age of the patient alone (150 IU in women less than 37 years old; 225 IU in 37 -39 year olds and 300 IU in women 40 years and above). Women with polycystic ovaries were started on 150 IU of FSH. Monitoring during the period of study was performed by ultrasound as well as serum estradiol. A human chorionic gonadotrophin (HCG) trigger was administered once at least three follicles of more than 17 - 18 mm diameter were visualized by ultrasound scan. Double-embryo transfer was the routine policy during the period to which the data relates (this has now changed to selective single-embryo transfer). Access to IVF was not determined by basal serum FSH.
Cost calculations
The resource use parameters in the ARUD [oocyte recovery, ultrasound scans, blood tests, medication used, embryo transfer, IVF/intracytoplasmic sperm injection (ICSI)] were costed using a bottom-up approach. All resource inputs (staff, equipment, space and consumables) required for individual procedures were identified and measured through consultation with appropriate clinicians and valued using 2006 -2007 market prices as detailed in the ARU budget (Table II) . Staffing costs were valued using the appropriate University of Aberdeen pay scales for 2006 -2007, taking account of employer's superannuation and National Insurance contributions. Discounting was not necessary as all costs considered, from treatment to live birth, occurred within the space of a year (2006) (2007) , i.e. most recent costs were applied across the whole period. Hence costs were standardized to the years 2006 -2007. However, capital items were annuitized over their expected useful lifespan using a discount rate of 3.5%.
Costs for OHSS were estimated using average costs for gynaecological outpatient visits and inpatient admissions in the Grampian region of Scotland (http://www.isdscotland.org/isd/costs-book-detailed-tables.js). OHSS was defined as mild, moderate and severe (Mathur et al., 2005) . It was assumed that, on average, mild OHSS would require two outpatient consultations, moderate OHSS would require 2 days of hospital admission and two outpatient consultations, and severe OHSS would require 5 days of hospital admission and two outpatient attendances (based on clinical judgement and average practice in our centre).
The cost of a biochemical pregnancy (defined as pregnancy that fails after positive pregnancy test, prior to ultrasound detection) was calculated by assuming that each, on average, would require one ultrasound scan and three blood tests for bHCG. The cost of miscarriage was taken as the average of medical and surgical termination of pregnancy obtained from the NHS Reference Costs on health-related groups (http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4133221). The cost of an ectopic pregnancy (treated surgically) was taken as the average cost of a Gynaecology day case in Grampian (http://www.isdscotland.org/isd/costs-book-detailed-tables. jsp) plus the cost of two bHCG blood tests. The cost of medical treatment of ectopic pregnancy was calculated using bottom-up calculation. Average daily costs of inpatient stay in the maternity and gynaecology units in Grampian were also obtained from ISD financial returns as were the unit costs of outpatient attendances. The costs of antenatal ultrasound and amniocentesis were obtained from the ultrasound department of Aberdeen Maternity Hospital (Table II) .
Statistical analysis
Extracted variables were analysed using the statistical package SPSS version 15 for Windows. Parametric tests were used to compare groups on normally distributed variables and non-parametric tests were used when data were skewed. 95% confidence intervals were estimated as appropriate. All the events occurring until the diagnosis of ongoing pregnancy (viable pregnancy up to 11 weeks) are recorded in the ARU database. Hence, patient-level resource use data were available for all patients up to this stage. Events in the antenatal period (after 11 weeks of gestation) were available only for women who delivered and had antenatal care in Aberdeen. Costs of IVF for overweight or obese women equation (derived from complete cases) was used to impute values for these services, where these were missing. The independent variables included in the regression model were multiple pregnancies (yes/no), BMI, age and year of delivery. Hence, we were able to estimate the cost of IVF treatment itself, early pregnancy care and antenatal care for each woman in the dataset. The average cost per pregnancy within each BMI group was derived by dividing the total IVF treatment costs incurred by the number of pregnancies in that group. The average cost per ongoing pregnancy in each BMI group was calculated as the total cost of IVF treatment and early follow-up (to 11 weeks) in each group, divided by the total number of ongoing pregnancies achieved during treatment. Finally, the average cost per live birth in each BMI group was calculated as the total cost (cost of IVF, cost of early follow-up, antenatal care and delivery) in each group, divided by the total number of live births achieved during treatment.
Uncertainty surrounding point estimates of the cost per live birth in each BMI group was characterized using the non-parametric bootstrap technique (Briggs et al., 2002) . Using this method, 1000 estimates of the mean cost per live birth were obtained for each BMI group by randomly drawing 1000 bootstrap re-samples of cost/effect pairs (with replacement) from the original sample. The 2.5th and the 97.5th percentile points were taken as the lower and upper 95% confidence limits for the point estimates.
Linear regression was used to explore the effect of BMI on costs after adjusting for appropriate variables. Chi-squared test for trend was used to explore the effect of BMI on clinical outcomes.
Sensitivity analysis was undertaken to assess the impact on findings of the following changes to key parameters and assumptions: (i) the cost of oocyte recovery was replaced with the cost of day surgery admission in Grampian, (ii) the cost of ectopic pregnancy was replaced using NHS reference cost for upper genital tract intermediate laparoscopic procedures and (iii) the missing cost of antenatal care data was imputed using mean values for BMI groups, rather than regression imputation.
Results
A total of 1854 women underwent their first cycle of IVF from 1997 to 2006. Of them, 98 did not have BMI recorded. Of the remaining 1756 women included in the analysis, 43 (2.4%) were underweight; 988 (56.3%) had normal BMI; 491 (28.0%) were overweight; 148 (8.4%) were obese (class I) and 86 (4.9%) were obese (class II), according to the WHO classification of obesity. There was slight increase in proportion of overweight and obese women over the study period (44.5% in 1997 to 51.4% in 2006, P ¼ 0.19). OHSS occurred in 10.2% (180) women; seven of these cases were classed as severe.
Of the 1756 women, 618 (35.1%) had a positive pregnancy test while 178 (28.8% of those with positive pregnancy test) women had early pregnancy loss (miscarriage and ectopic pregnancy). Of all women, with known BMI, who started treatment, 433 (24.7%) had a live birth. Characteristics of women in each BMI groups are given in Table III . Women in underweight category were younger. Duration of infertility and the insemination technique used (IVF or ICSI) was similar across the BMI groups. Incidence of anovulation was higher in obese women. The total dose of gonadotrophins used increased as the BMI increased. The incidence of cycle cancellation was comparable in the BMI groups (Table III) groups in terms of the proportion of women having a positive pregnancy, ongoing pregnancy and live birth. There was a trend towards a lower live birth rate with increasing BMI, though the difference was not statistically significant. A slightly higher proportion of women (who started the treatment), in overweight and obese groups had early pregnancy loss [9.3% among underweight group; 8.8% among those with normal BMI; 11.2% among overweight; 12.8% among obese and 15.1% among women in the obese II category (chi-squared test for trend P ¼ 0.57)]. Amongst women who became pregnant, a higher proportion had miscarriages in obese class II (26.7% in underweight group; 25.0% among those with normal BMI; 32.4% among overweight; 35.8% among obese and 40.6% among women in the obese II category (chi-squared test for trend, P ¼ 0.01). The proportion of women having multiple pregnancies was similar in all groups.
The mean cost of IVF treatment cycle was similar across the BMI groups (P ¼ 0.43) ( Table V) . Regression of cost on BMI (with and without adjusting for age of the female partner) did not show an increase in cost with BMI (P ¼ 0.9). Similar results were obtained after excluding women who were underweight (P ¼ 0.16).
Of the 433 women with an ongoing pregnancy, 278 (64.2%) had antenatal care in Aberdeen (Fig. 1) . Of the remaining 155 who had antenatal care elsewhere, 2 women were underweight; 94 had BMI 18.5 -24.9; 37 had BMI 25 -29.9; 16 had BMI 30 -34.9 and 6 had a BMI 35. We did not have details of antenatal care and deliveries for these women. On the assumption that organization and delivery of antenatal care is similar throughout the National Health Services in Scotland, we imputed the cost of antenatal care and delivery in these women using logistic regression as described in the Materials and Methods section. Hence, in the final analysis all women were included.
Details of antenatal and delivery period for women who had antenatal care in Grampian are given in Table IV . Similar proportions of women in all four groups had multiple pregnancies, instrumental deliveries and Caesarean sections. A higher proportion of women had epidural in underweight group. A higher proportion of women in obese class II had ante-partum haemorrhage and diabetes, although the actual numbers were small. There was no difference in the incidence of other complications (pregnancy induced hypertension, preterm deliveries) between the groups based on complete case analysis (Table IV) . The median costs for antenatal care and delivery were similar across the groups (Table V) . On linear regression of cost (after log conversion) on BMI there was no increase in the cost with increase in BMI (P ¼ 0.44). The results were similar when underweight women were excluded from analysis (P ¼ 0.22).
The mean cost per positive pregnancy test, per ongoing pregnancy and per live birth was similar across the groups (Table V) . We performed a sensitivity analysis to assess the impact of using average costs, as opposed to our own patient level estimates (data not shown). This had no impact on the overall findings.
Discussion
We found no significant difference in the cost per live birth resulting from ART in women who are overweight and obese (class 1) compared with women with normal BMI. The average cost of ART treatment itself, as well as cost of antenatal care, was comparable in all five BMI groups. The number of women in obese class II was small. Overweight and obese women required higher doses of gonadotrophins and were more likely to miscarry when they got pregnant.
We have used patient level data as opposed to modelling techniques, used by most economic evaluations. The cost of early pregnancy complications, as well as the cost of antenatal care from a single centre, is taken into account in addition to the cost of the IVF cycle to determine the cost of live birth.
We have looked only at the cost of the first treatment cycle in each woman. Many studies have reported more than one pregnancy per woman (Wittemer et al., 2000; Nichols et al., 2003) . Studies having more than one pregnancy per woman are taking cycle per pregnancy as denominator rather than woman. Using women as the denominator is accepted to be the more robust method (Vail and Gardener, 2003) , as it is the women who are generally accepted to be the unit of analysis. Expressing outcomes per pregnancy can lead to significant bias, especially where some woman can have more than one pregnancy. Moreover, the issue of time comes into play when more than one cycle per women is taken.
Our results should be viewed with caution as the study performed is limited to a well-defined geographical area and may not be representative for whole of the population in UK as every area has different demographics.
Overweight and obese are defined in this study according to WHO BMI groupings. However, controversy surrounds the use of BMI as an indicator for obesity, and it has been suggested that that waist-hip ratio correlates better with health and fertility outcomes (Wass et al., 1997) . Further research is required to examine the relationship between waist -hip ratio and ART outcomes. As obesity is increasingly seen to be a worldwide problem, it is necessary to have a single international standard. The popularity of BMI can be ascribed to its ease of measurement and lack of susceptibility to inter and intra-observer variations.
We noted an association between obesity and ovulatory dysfunction, a fact which has been noted before (Clark et al., 1995) . Despite this, it is possible that treating women with supraphysiological dose of gonadotrophins may well override subtle differences in the levels of hypothalamic ovarian sensitivity. Previous studies have reported that requirement of gonadotrophins is increased in overweight and obese women. This is similar to our results, which showed an increase in gonadotrophin requirement in obese class II. This is despite the fact that our protocols do not involve modification of dose according to BMI for the first IVF cycle, unlike some other units (Dechaud et al., 2006) . There are no randomized controlled trials, to date, evaluating whether overweight and obese women have better outcomes with higher dose of gonadotrophins. There was increase in proportion of women who had early pregnancy loss as BMI increased in the present study. This is supported by some earlier studies (Wang et al., 2000; Winter et al., 2002) ; while others have not found an increased miscarriage rate in overweight and obese women (Lashen et al., 1999; Dechaud et al., 2006) . The difference in the findings might be explained by different ways of reporting (miscarriage rates per women who started the cycle as denominator rather than per pregnancy).
There are variable reports of the impact of overweight status and obesity on outcomes in ART, with some studies showing poorer outcomes (Fedorcsak et al., 2004) while others show no impact (Dechaud et al., 2006) . We did not find any statistically significant differences in the live birth rate among women in different BMI categories, which agree with the results of a systematic review done by our group (Maheshwari et al., 2007) . The sample size in our present study may not be large enough to allow us to detect small differences in the live birth rate (if there are any). It is worth noting that analysis of a far larger number (a total of 3877 women) in the systematic review failed to demonstrate any differences in live birth among BMI groups (until BMI 35).
There was no difference in antenatal complications apart from increased incidence of gestational diabetes in obese women. However, as the actual numbers of women with diabetes were small, this did not result in a significant difference in the costs. This may be due to the fact that most women (including those with higher BMI) undergoing ART who went on to become pregnant, were a self-selected group of women who were otherwise fit and healthy. The numbers in BMI group over 35 are small in this and other studies reporting on this topic. Hence, we cannot comment on the ART success rates and outcomes in this group (i.e. obesity class II) with confidence. However, there is wealth of evidence of effect of pre-pregnancy BMI on adverse obstetrical and neonatal outcomes (Abenhaim et al., 2007) . As infertility healthcare providers, we have the unique opportunity to prevent these complications through preconception weight loss and hence weight loss should be recommended even for overweight women.
Conclusions
Our results suggest that there is not enough evidence to indicate that being overweight or obese (class I) significantly increases the costs of ART. Women should be counselled that they are more likely to miscarry if they are overweight or obese. In addition, weight loss is important for improving general health and obstetric outcomes, hence should be encouraged.
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